NEW YORK, Dec 20 - Third Wave Technologies said Wednesday it would provide its Invader SNP detection operating system to Cambridge University and Catalyst BioMedica, the Wellcome Trust’s business subsidiary, as part of a research collaboration to study Type 1 diabetes.
" Third Wave's Invader SNP typing system was chosen because the Invader chemistry works,” John Todd, the director of Cambridge University’s Diabetes and Inflammation Laboratory, said in a statement. “Third Wave is one of the first to consider, and actually implement the scale-up required for whole genome -scale gene association studies."
Under the terms of the agreement, Third Wave of Madison, Wis., will receive certain rights to commercialize discoveries made under the agreement for research and diagnostic medical applications. The company will also offer additional support to help discover the genetic differences that make certain people susceptible to Type 1 diabetes and other inflammation-related diseases.
Third Wave said the collaboration would help to increase its understanding of the genetic basis of disease and to bring it closer to being able to implement strategies for personalizing medicine.
A spokesperson from the company was not immediately available for comment.
In November the Wellcome Trust and the Juvenile Diabetes Research Foundation International announced a five-year $32 million award to establish the Cambridge Diabetes and Inflammation Laboratory.
The laboratory plans to conduct SNP studies based on samples gathered from 10,000 people with diabetes and an equal number from healthy individuals.
In September Third Wave signed a similar deal with the Imperial College of Great Britain, Royal Brompton's Hospital, and the UK National Health Service Trust to identify a genetic basis for cardiac and pulmonary diseases.